Table 1.
Baseline characteristics per treatment group and overall at enrollment*
| Characteristics | Regimen (AS+AQ)(N = 260) | Regimen (AS+SP)(N = 260) | Regimen (AL)(N = 260) | P value |
|---|---|---|---|---|
| Age (years) | ||||
| Mean ± SD | 5.37 ± 6.19 | 5.23 ± 4.1 | 5.94 ± 6.8 | 0.51 |
| Median (min, max) | 4.1 (0.5,68.6) | 4.3(0.5,30.5) | 4.3(0.5,46.6) | |
| Age category n (%) | 0.72 | |||
| < 5 | 155 (59.6) | 147 (56.5) | 146 (56.2) | |
| 5–9 | 78 (30.0) | 85 (32.69) | 88 (33.9) | |
| 10–14 | 18 (6.9) | 21 (8.1) | 14 (5.4) | |
| ≥ 15 | 9 (3.5) | 7 (2.7) | 12 (4.6) | |
| Gender – n (%) | ||||
| Female | 142 (54.6) | 129 (49.6) | 130 (50.0) | 0.45 |
| P. falciparum (/μL) | ||||
| Median (Q1,Q3) | 21,550 (10,375, 45,150) | 23,225 (9,990, 44,190) | 21,925 (10,440, 42,050) | 0.99 |
| Gametocyte– n (%) | 16 (6.2) | 18 (6.9) 28 (10.8) | 0.11 | |
*
n = frequency; Q1 = 25th percentile; Q3 = 75th percentile; Min = minimum; Max = maximum; AL = artemether-lumefantrine; AS+AQ = artesunate plus amodiaquine; AS+SP = artesunate plus sulfadoxine-pyrimethamine.